Women’s Health
8 min read
22 May 2026
PCOS Has Been Renamed. Here Is Why It Matters.
After 14 years of global consultation and input from 22,000 patients, polycystic ovary syndrome is now officially polyendocrine metabolic ovarian syndrome. The name change is not cosmetic.
Jon Bell
Metabolic Health Specialist · Leamington Spa
On 12 May 2026, a paper published in The Lancet formally renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome, abbreviated PMOS. The paper was led by Professor Helena Teede of Monash University in Melbourne, representing a Global Name Change Consortium of researchers, clinicians, and patient advocates from across the world. It was announced simultaneously at the European Congress of Endocrinology in Prague.
The renaming process took 14 years and involved structured consultation with more than 22,000 patients and healthcare professionals. It is not a rebranding exercise. It is a correction of a clinical misrepresentation that has shaped, and in many ways limited, the medical response to this condition for decades.
Why the Old Name Was Wrong
The term ‘polycystic ovary syndrome’ originated in the 1930s, when surgeons operating on women with certain hormonal features noticed what appeared to be small follicles on the ovarian surface. They described these as cysts, and the name stuck. The problem is that the observation was both anatomically imprecise and diagnostically misleading on multiple levels.
- The 'cysts' are not cysts. They are small, undeveloped follicles that fail to complete the maturation process. This failure is a consequence of the underlying hormonal disruption, not a pathology of the ovary itself.
- Polycystic ovarian morphology is present in up to 30% of women who do not have the syndrome. Conversely, a significant proportion of women who do have the syndrome do not have visibly polycystic ovaries at all.
- The ovaries are not the origin of the condition. They are one site at which the downstream consequences of hormonal and metabolic dysregulation become visible.
- The name directed clinical attention toward the reproductive system and away from the systemic metabolic dysfunction that drives the condition.
"For many women, a PCOS diagnosis has historically meant a conversation about fertility and menstrual irregularity. The metabolic picture, the insulin resistance, the elevated androgens, the cardiovascular risk, was often addressed only if the patient pressed for it."
What PMOS Actually Describes
The new name, polyendocrine metabolic ovarian syndrome, has three components that each carry specific clinical weight. ‘Polyendocrine’ acknowledges that the condition involves multiple hormone systems simultaneously: insulin and its regulation, androgens (male sex hormones, which are elevated in PMOS), the hypothalamic-pituitary-ovarian axis, and in many cases the thyroid and adrenal systems. ‘Metabolic’ correctly identifies insulin resistance as the primary driver in the majority of cases. ‘Ovarian’ retains the reproductive dimension, which remains a significant part of the clinical picture for many women.
Prevalence
170 million
The elevated lifetime risk of type 2 diabetes in women with PMOS compared to the general population, driven primarily by the underlying insulin resistance that characterises the condition.
Insulin Resistance at the Centre
The clinical significance of the rename is that it formally places insulin resistance where the evidence has long suggested it belongs: as the central mechanism in the majority of PMOS cases. Insulin resistance means the body’s cells respond poorly to insulin, requiring the pancreas to produce progressively more of it to maintain blood sugar control. In PMOS, chronically elevated insulin stimulates the ovaries and adrenal glands to produce excess androgens. These elevated androgens disrupt the maturation of follicles, producing the irregular cycles, delayed ovulation, and ovarian morphology that have historically defined the condition by name.
The consequence of this mechanism is that treating the reproductive symptoms without addressing the underlying insulin resistance is, in most cases, treating the wrong thing. Hormonal contraception may regulate cycles. It does not correct insulin sensitivity. Metformin may reduce insulin levels, but it is a pharmaceutical intervention targeting a single pathway of a systemic metabolic problem.
The Metabolic Risk That Comes With PMOS
Women with PMOS carry a significantly elevated risk of type 2 diabetes, with some studies placing the lifetime risk at three to seven times that of women without the condition. They also carry elevated cardiovascular risk, driven by the same insulin resistance, elevated androgens, and the dyslipidaemia that frequently accompanies it: raised triglycerides, reduced HDL, and a shift toward the atherogenic small-dense LDL pattern. These risks are not secondary features of the condition. They are the metabolic expression of the same underlying dysfunction that produces the ovarian and hormonal symptoms.
Type 2 diabetes risk
3 to 7x
The elevated lifetime risk of type 2 diabetes in women with PMOS compared to the general population, driven primarily by the underlying insulin resistance that characterises the condition.
What the Rename Changes in Practice
At the level of clinical care, the rename carries several practical implications. A diagnosis that explicitly names metabolic dysfunction should, in principle, trigger metabolic assessment: fasting insulin, HbA1c, full lipid panel, and ideally a CGM assessment to understand glucose behaviour in real time. It should frame the conversation around long-term cardiometabolic risk, not solely around fertility. And it should prompt genuine discussion of lifestyle intervention as a primary, rather than adjunctive, treatment.
The women Jon works with who carry a PMOS diagnosis share a consistent metabolic profile: elevated fasting insulin, often before glucose has moved out of the normal range; raised triglycerides; suppressed HDL; and significant post-meal glucose variability on CGM. These markers respond well to the structured metabolic intervention that the Six Pillar Method provides. Not because it is designed specifically for PMOS, but because it addresses insulin resistance directly, which is the correct target regardless of what the condition is named.
"A name that finally reflects the biology is not just a semantic correction. It is an invitation to treat the right thing, with the right tools, from the start."
Frequently Asked
Why the Old Name Was Wrong
The term ‘polycystic ovary syndrome’ originated in the 1930s, when surgeons operating on women with certain hormonal features noticed what appeared to be small follicles on the ovarian surface. They described these as cysts, and the name stuck. The problem is that the observation was both anatomically imprecise and diagnostically misleading on multiple levels.
What PMOS Actually Describes
The new name, polyendocrine metabolic ovarian syndrome, has three components that each carry specific clinical weight. ‘Polyendocrine’ acknowledges that the condition involves multiple hormone systems simultaneously: insulin and its regulation, androgens (male sex hormones, which are elevated in PMOS), the hypothalamic-pituitary-ovarian axis, and in many cases the thyroid and adrenal systems. ‘Metabolic’ correctly identifies insulin resistance as the primary driver in the majority of cases. ‘Ovarian’ retains the reproductive dimension, which remains a significant part of the clinical picture for many women.
Insulin Resistance at the Centre
The clinical significance of the rename is that it formally places insulin resistance where the evidence has long suggested it belongs: as the central mechanism in the majority of PMOS cases. Insulin resistance means the body’s cells respond poorly to insulin, requiring the pancreas to produce progressively more of it to maintain blood sugar control. In PMOS, chronically elevated insulin stimulates the ovaries and adrenal glands to produce excess androgens. These elevated androgens disrupt the maturation of follicles, producing the irregular cycles, delayed ovulation, and ovarian morphology that have historically defined the condition by name.
The Metabolic Risk That Comes With PMOS
Women with PMOS carry a significantly elevated risk of type 2 diabetes, with some studies placing the lifetime risk at three to seven times that of women without the condition. They also carry elevated cardiovascular risk, driven by the same insulin resistance, elevated androgens, and the dyslipidaemia that frequently accompanies it: raised triglycerides, reduced HDL, and a shift toward the atherogenic small-dense LDL pattern. These risks are not secondary features of the condition. They are the metabolic expression of the same underlying dysfunction that produces the ovarian and hormonal symptoms.